IL115733A - Binding agents to cd23 and their use in the manufacture of a medicament - Google Patents
Binding agents to cd23 and their use in the manufacture of a medicamentInfo
- Publication number
- IL115733A IL115733A IL11573395A IL11573395A IL115733A IL 115733 A IL115733 A IL 115733A IL 11573395 A IL11573395 A IL 11573395A IL 11573395 A IL11573395 A IL 11573395A IL 115733 A IL115733 A IL 115733A
- Authority
- IL
- Israel
- Prior art keywords
- binding agents
- medicament
- manufacture
- autoimmune
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9421463A GB9421463D0 (en) | 1994-10-25 | 1994-10-25 | Binding agents |
GBGB9512480.6A GB9512480D0 (en) | 1995-06-20 | 1995-06-20 | Binding agents |
GBGB9513415.1A GB9513415D0 (en) | 1995-06-30 | 1995-06-30 | Binding agents |
Publications (2)
Publication Number | Publication Date |
---|---|
IL115733A0 IL115733A0 (en) | 1996-01-19 |
IL115733A true IL115733A (en) | 1999-12-22 |
Family
ID=27267444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11573395A IL115733A (en) | 1994-10-25 | 1995-10-24 | Binding agents to cd23 and their use in the manufacture of a medicament |
Country Status (21)
Country | Link |
---|---|
US (2) | US6627195B1 (xx) |
EP (3) | EP0788514A1 (xx) |
JP (3) | JPH10507460A (xx) |
KR (1) | KR20040058016A (xx) |
CN (1) | CN1171119A (xx) |
AT (1) | ATE198895T1 (xx) |
AU (2) | AU710369B2 (xx) |
BR (2) | BR9509434A (xx) |
CA (2) | CA2203364A1 (xx) |
DE (1) | DE69519997T2 (xx) |
DK (1) | DK0788513T3 (xx) |
ES (1) | ES2154741T3 (xx) |
FI (1) | FI971756A0 (xx) |
HK (1) | HK1002765A1 (xx) |
HU (1) | HU223006B1 (xx) |
IL (1) | IL115733A (xx) |
MX (1) | MX9702797A (xx) |
NO (1) | NO971902L (xx) |
NZ (2) | NZ295158A (xx) |
PT (1) | PT788513E (xx) |
WO (2) | WO1996012742A1 (xx) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
US6893636B2 (en) | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
WO1999045777A1 (en) * | 1998-03-10 | 1999-09-16 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of asthma |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
AU1960100A (en) * | 1999-01-06 | 2000-07-24 | Mcmaster University | Method of preventing immune and hypersensitivity reactions |
EP1239877B1 (en) * | 1999-10-06 | 2008-01-09 | Abbott GmbH & Co. KG | Composition comprising a tnf-alpha inhibitor and an integrin alphavbeta3 receptor antagonist |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US6820011B2 (en) | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
CN100460015C (zh) * | 2003-02-14 | 2009-02-11 | 上海张江生物技术有限公司 | 免疫调节剂及其应用 |
JP2006522811A (ja) * | 2003-04-09 | 2006-10-05 | ジェネンテック・インコーポレーテッド | TNFαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法 |
EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
EP1733231B1 (en) * | 2004-04-05 | 2011-05-04 | Université Bordeaux 2 | Peptides and peptidomimetics binding to cd23 |
WO2006017574A1 (en) * | 2004-08-03 | 2006-02-16 | Mayo Foundation For Medical Education And Research | Improving treatments |
US20090291048A1 (en) * | 2005-10-25 | 2009-11-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Leukocyte-binding polypeptides and uses thereof |
RU2489166C2 (ru) * | 2006-04-09 | 2013-08-10 | Джинентех, Инк. | Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
CA2656063C (en) | 2006-06-21 | 2016-10-18 | Musc Foundation For Research Development | Targeting complement factor h for treatment of diseases |
WO2009043051A2 (en) * | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
EP2496259B1 (en) | 2009-11-05 | 2017-02-22 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria |
US9650447B2 (en) | 2010-05-14 | 2017-05-16 | The Regents Of The University Of Colorado, A Body Corporate | Complement receptor 2 (CR2) targeting groups |
EA201291328A1 (ru) | 2010-06-22 | 2013-10-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт | АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3 |
KR101813482B1 (ko) * | 2010-11-24 | 2017-12-29 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 | 루푸스의 치료 또는 예방을 위한 조성물 및 방법 |
US10017762B2 (en) * | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946788A (en) * | 1985-06-11 | 1990-08-07 | Ciba-Geigy Corporation | Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications |
FR2599513B1 (fr) * | 1986-05-27 | 1989-09-15 | Unicet Laboratoires | Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation |
GB8726230D0 (en) * | 1987-11-10 | 1987-12-16 | Rosen H | Antibodies |
EP0321842A1 (en) * | 1987-12-22 | 1989-06-28 | Kishimoto, Tadamitsu, Prof. | Soluble recombinant Fc-Epsilon-receptor, the preparation and the use thereof |
DE3830271A1 (de) * | 1988-09-06 | 1990-03-15 | Goetze Otto | Mittel mit immunsuppressiver wirkung |
WO1990004176A1 (en) * | 1988-10-03 | 1990-04-19 | Scripps Clinic And Research Foundation | THE RECEPTOR BINDING REGION OF EBVgp350 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE912528A1 (en) * | 1990-07-19 | 1992-01-29 | Scripps Clinic Res | Inhabition of mac-1 receptor binding fibrinogen using d30¹homologs |
AU673499B2 (en) * | 1991-07-25 | 1996-11-14 | Biogen Idec Inc. | Recombinant antibodies for human therapy |
WO1993009803A1 (en) * | 1991-11-22 | 1993-05-27 | The Scripps Research Institute | Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation |
US5766943A (en) * | 1992-08-17 | 1998-06-16 | University Of Iowa Research Foundation | DNA sequences for soluble form of CD23 |
EP0670734A4 (en) * | 1992-10-09 | 1998-01-14 | Blood Res Center | SUB-POPULATION OF Mac-1 MOLECULES (CD11B / CD 18) THAT INDUCE NEUTROPHILIC ADHESION TO ICAM-1 AND FIBRINOGEN. |
-
1995
- 1995-10-20 EP EP95937803A patent/EP0788514A1/en not_active Withdrawn
- 1995-10-20 MX MX9702797A patent/MX9702797A/es not_active Application Discontinuation
- 1995-10-20 AU AU38679/95A patent/AU710369B2/en not_active Ceased
- 1995-10-20 EP EP95936525A patent/EP0788513B1/en not_active Revoked
- 1995-10-20 BR BR9509434A patent/BR9509434A/pt not_active Application Discontinuation
- 1995-10-20 HU HU9800339A patent/HU223006B1/hu not_active IP Right Cessation
- 1995-10-20 ES ES95936525T patent/ES2154741T3/es not_active Expired - Lifetime
- 1995-10-20 US US08/817,719 patent/US6627195B1/en not_active Expired - Fee Related
- 1995-10-20 NZ NZ295158A patent/NZ295158A/en unknown
- 1995-10-20 AU AU38435/95A patent/AU698158B2/en not_active Ceased
- 1995-10-20 WO PCT/EP1995/004110 patent/WO1996012742A1/en not_active Application Discontinuation
- 1995-10-20 NZ NZ295352A patent/NZ295352A/en unknown
- 1995-10-20 PT PT95936525T patent/PT788513E/pt unknown
- 1995-10-20 AT AT95936525T patent/ATE198895T1/de not_active IP Right Cessation
- 1995-10-20 WO PCT/EP1995/004109 patent/WO1996012741A1/en not_active Application Discontinuation
- 1995-10-20 JP JP8513642A patent/JPH10507460A/ja active Pending
- 1995-10-20 DE DE69519997T patent/DE69519997T2/de not_active Expired - Fee Related
- 1995-10-20 CA CA002203364A patent/CA2203364A1/en not_active Abandoned
- 1995-10-20 KR KR10-2004-7006304A patent/KR20040058016A/ko not_active Application Discontinuation
- 1995-10-20 DK DK95936525T patent/DK0788513T3/da active
- 1995-10-20 EP EP99204301A patent/EP1018517A3/en not_active Withdrawn
- 1995-10-20 CN CN95197075A patent/CN1171119A/zh active Pending
- 1995-10-20 JP JP51350896A patent/JP3323508B2/ja not_active Expired - Fee Related
- 1995-10-20 BR BR9509498A patent/BR9509498A/pt not_active Application Discontinuation
- 1995-10-20 CA CA002203363A patent/CA2203363A1/en not_active Abandoned
- 1995-10-24 IL IL11573395A patent/IL115733A/xx not_active IP Right Cessation
-
1997
- 1997-04-24 FI FI971756A patent/FI971756A0/fi not_active IP Right Cessation
- 1997-04-24 NO NO971902A patent/NO971902L/no not_active Application Discontinuation
-
1998
- 1998-02-12 HK HK98101085A patent/HK1002765A1/xx not_active IP Right Cessation
-
2001
- 2001-04-25 JP JP2001127383A patent/JP2001316291A/ja active Pending
-
2003
- 2003-08-04 US US10/632,852 patent/US20040022783A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL115733A (en) | Binding agents to cd23 and their use in the manufacture of a medicament | |
FI944549A (fi) | Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet | |
IL119462A0 (en) | Pyrrolopyrimidines | |
IL129358A0 (en) | Novel heterocyclically substituted benzamides and their use in fighting diseases | |
CY2508B1 (en) | Benzopyrans and their use as therapeutic agents | |
AU2466695A (en) | The use of famotidine and related compounds in the treatment of movement disorders | |
GB8908831D0 (en) | Treatment of inflammatory disorders in humans | |
ZA958838B (en) | The use of vwf-containing concentrates as a therapy which is employed in combination with antithrombotic and fibrinolytic therapy | |
HUP0000785A3 (en) | Ointment for the treatment of burns and other skin diseases | |
EP0453658A3 (en) | Use of substituted anilides and sulfonamides in the treatment of cardiovascular diseases | |
EP0427427A3 (en) | Use of arylalkylamides in the treatment of neurodegenerative diseases | |
GB9424708D0 (en) | Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage | |
AU5461590A (en) | 2-imino-thiadiazoline-5-sulphonamides and their use in the treatment of glaucoma | |
WO1994006345A3 (en) | Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof | |
AU2153092A (en) | Spirofurane derivatives and their use in the treatment of neurological disorders | |
EP0456204A3 (en) | Use of benzocycloheptathiophenecarboxylic acid derivatives in the treatment of eosinophile accumulation/activation and connected diseases | |
ZA879420B (en) | 5-aryl-3h-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | |
CU21316A1 (en) | Skin carrier to the use in mechanic dermo-expandor (meshgraft ii and mod-i) to the treatment and rehabilitation in patient with serious burns | |
AU4449896A (en) | Use of beta-cell-tropin (ACTH 22-39) antagonists in the treatment of type II diabetes and associated diseases | |
LV11105A (lv) | Arstniecibas lidzeklis ar pretinfekciju iedarbibu un ta pielietojums infekcijas slimibu arstesanai | |
ZA954732B (en) | Benzopyrans and their use as therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |